Table 2: Summary of kidney outcome trials with sodium–glucose co-transporter-2 inhibitors^21–23.

Trial	CREDENCE (n=4,401)	DAPA-CKD (n=4,304)	SCORED (n=10,584)
Treatment	Canagliflozin versus placebo	Dapagliflozin versus placebo	Sotagliflozin versus placebo
Mean participant age (years)	63	62	69
Key inclusion criteria	T2D eGFR 30 to <90 mL/min/1.73 m2 UACR >300 to 5,000 mg/g Treated with RAS inhibitor for ≥4 weeks prior to randomization	eGFR 25–75 mL/min/1.73 m2 UACR of 200–5,000 mg/g Treated with RAS inhibitor for ≥4 weeks prior to screening	T2D eGFR 25–60 mL/min/1.73 m2 Presence of ≥1 additional cardiovascular risk factor
Baseline diagnosis of T2D (%)	100	67	100
Mean baseline HbA1c (%)	8.3	7.1	8.3
Baseline metformin use (%)	58	29	55
Median follow-up (years)	2.6	2.4	1.3
Primary outcome
HR (95% CI)	End-stage kidney disease, doubling of serum creatinine, or renal or cardiovascular death 0.70 (0.59–0.82)	≥50% decline in eGFR, end-stage kidney disease, or renal or cardiovascular death 0.61 (0.51–0.72)	Total number of cardiovascular deaths, HF hospitalizations, or urgent visits for HF 0.74 (0.63–0.88)
Key secondary outcomes
Progression to end-stage kidney disease; HR (95% CI)	0.68 (0.54–0.86)	0.64 (0.50–0.82)	N/R
Cardiovascular death; HR (95% CI)	0.78 (0.61–1.00)	0.81 (0.58–1.12)	0.90 (0.73–1.12)
All-cause mortality; HR (95% CI)	0.83 (0.68–1.02)	0.69 (0.53–0.88)	0.99 (0.83–1.18)

CI = confidence interval; CVD = cardiovascular disease; eGFR = estimated glomerular filtration rate; HbA1c = glycated haemoglobin A1c; HR = hazard ratio; N/R = not reported; RAS = renin-angiotensin system; T2D = type 2 diabetes mellitus; UACR = urinary albumin-to-creatinine ratio.